Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polar Explorer trial of reduced-dose pola-R-CHP in older adults with newly diagnosed DLBCL
jRCT1051250075Phase 2Recruiting
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisolone in diffuse large B-cell lymphoma (DLBCL) (2 cohorts). Primary endpoint: Progression-free survival. Started Aug 2025; status: recruiting.
02
Drugs
polatuzumab vedotinrituximabcyclophosphamidedoxorubicinprednisolone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT1051250075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051250075.